The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Postoperative Pain
Interventions
DRUG

Morphine

38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.

DRUG

Morphine plus Nalbuphine

39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.

Trial Locations (1)

Unknown

Assiut university faculty of medicine, Asyut

All Listed Sponsors
lead

Abdelrady S Ibrahim, MD

OTHER

NCT02716129 - The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section | Biotech Hunter | Biotech Hunter